Slingshot members are tracking this event:

Late-Breaking Presentation at EAACI Highlights Viaskin Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details Data presented evaluated biomarkers from children who underwent three double-blind, placebocontrolled food challenges (DBPCFC) during VIPES and OLFUS-VIPES: at baseline, year-1 and year-2 of treatment with Viaskin Peanut. Concentrations of serum biomarkers (including peanut-specific IgE [p-sIgE], peanut-specific IgG4 [p-sIgG4] and Ara h 2 p-sIgE [a2-sIgE]) and other variables were collected before each challenge. In this study, the DBPCFC outcome was modeled as a binary endpoint defined by three reactive threshold doses of 300 mg, 1000 mg and 2000 mg. Very short signatures of two to four variables measured predictability of response to the OFC for all three models. The ratios p-sIgG4/a2-sIgE and p-sIgG4/p-sIgE were always among the top-ranked variables. Based on these results, the researchers concluded that modeling the response to an oral food challenge based on a subset of serum biomarkers is feasible, and the model may eventually be employed to monitor treatment progression with Viaskin Peanut.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 15, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Viaskin, Peanut Allergy